GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Alkermes plc
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders (schizophrenia, addiction). Its share price depends on the commercial success of its drugs and generic competition, which creates ongoing challenges.
Share prices of companies in the market segment - Pharma psycho
Alkermes is a biopharmaceutical company focused on treating central nervous system disorders, such as schizophrenia and addiction. We classify it as part of the Pharma Psychotherapy sector, and the chart below shows the overall performance of this segment.
Broad Market Index - GURU.Markets
Alkermes is an Irish biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. As a significant player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Alkermes' performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
ALKS - Daily change in the company's share price Alkermes plc
The daily price change of Alkermes, which operates in the complex field of central nervous system diseases, reflects the high volatility inherent in biotech. Change_co tracks the market's reaction to research news and regulatory decisions. This indicator is an essential element in building formulas on System.GURU.Markets that measure stock news sensitivity.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Alkermes plc is a biotech company. This chart highlights the sector's high volatility. Comparing it to ALKS, which focuses on CNS diseases, helps assess its risks compared to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, including schizophrenia and addiction. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Alkermes plc
Alkermes is a biopharmaceutical company specializing in the treatment of central nervous system disorders and addictions. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Alkermes plc is a biopharmaceutical company specializing in the treatment of central nervous system disorders, such as schizophrenia and addiction. The chart shows how its portfolio of commercialized drugs and the clinical trial results of new candidates influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alkermes is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Alkermes plc
Alkermes, a biopharmaceutical company specializing in central nervous system disorders (schizophrenia, addiction). The monthly fluctuations on the chart reflect sales data for its key drugs and news about clinical trials of new developments.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
This chart reflects the dynamics of the biotech sector. For Alkermes, a company focused on the central nervous system, it's the backdrop. Its movements show how the commercial success of its approved drugs and progress in clinical trials influence its valuation in a volatile sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. The overall market performance chart allows us to assess how investors perceive Alkermes: as a stable company with commercial products or as a biotech whose value is more dependent on development news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Alkermes plc
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. Its weekly stock price is heavily dependent on clinical trial data and the sales success of its key drugs. The chart reflects the risks and prospects of treating complex diseases.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Alkermes is a pharmaceutical company that often reacts to industry-wide events, such as healthcare reforms. The chart compares the company's performance with the overall health of its large and diverse segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Alkermes is a biopharmaceutical company specializing in CNS diseases. Its shares follow the rhythm of news about clinical trials and drug sales. The chart will show how its weekly performance is detached from overall market trends, driven by its own unique events.
Market capitalization of the company, segment and market as a whole
ALKS - Market capitalization of the company Alkermes plc
Alkermes plc's chart tells the story of developing complex drugs for treating central nervous system disorders such as schizophrenia and addiction. Its market capitalization reflects both the success of commercialized drugs and investor confidence in the company's future developments in one of the most complex areas of medicine.
ALKS - Share of the company's market capitalization Alkermes plc within the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. Its share of the sector's market capitalization reflects the commercial success of its products. The chart shows how competition and drug development impact its market share in this complex field.
Market capitalization of the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. How big is this arena? The chart below shows the total market capitalization of the psychopharmaceutical sector. Its growth reflects the enormous need for new treatments for mental disorders.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Alkermes chart reveals the complex story of a biopharmaceutical company focused on central nervous system disorders such as schizophrenia and addiction. Its market capitalization is a blend of revenue from existing drugs and hopes for new developments. This diagram reflects the challenges and potential in one of the most complex areas of medicine.
Book value capitalization of the company, segment and market as a whole
ALKS - Book value capitalization of the company Alkermes plc
Alkermes, a biopharmaceutical company, has a book value comprised of its drug manufacturing facilities, R&D centers, and significant financial reserves. This provides the company with the material foundation for drug development and commercialization. The chart below shows the dynamics of the value of this physical and financial capital.
ALKS - Share of the company's book capitalization Alkermes plc within the market segment - Pharma psycho
Alkermes plc is a biopharmaceutical company whose assets include modern manufacturing and research facilities in Ireland and the United States. These facilities produce complex medications for the treatment of addictions and mental disorders. The chart shows the company's control over this high-tech pharmaceutical infrastructure.
Market segment balance sheet capitalization - Pharma psycho
Alkermes is a biopharmaceutical company with its own manufacturing facilities, making it more capital-intensive than purely R&D-focused startups. The chart below illustrates the scale of the entire pharmaceutical sector, providing context for assessing its integrated model.
Book value of all companies included in the broad market index - GURU.Markets
Alkermes plc is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. Its assets include R&D and manufacturing facilities. Its stake in BCap_All provides the necessary resources for the development and production of drugs that address complex medical problems.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Alkermes plc
Alkermes is a biopharmaceutical company. Its balance sheet is its manufacturing plants. Its market valuation is the value of its approved drugs for addiction and schizophrenia. The premium to its balance sheet is the reward for its commercial success and pipeline of future developments.
Market to book capitalization ratio in a market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. The chart shows the premium investors pay for its portfolio of commercialized drugs and developments over the value of its physical assets.
Market to book capitalization ratio for the market as a whole
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart shows the average market valuation. This valuation reflects both stable revenues from existing products and the potential for new developments.
Debts of the company, segment and market as a whole
ALKS - Company debts Alkermes plc
Alkermes, a biopharmaceutical company specializing in CNS diseases, uses debt capital to finance the commercialization of its products and conduct research. The company's debt strategy is aimed at securing sufficient funds for the marketing of already approved drugs and advancing promising candidates through clinical trials.
Market segment debts - Pharma psycho
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. Developing such complex drugs requires long-term investments in R&D. This chart shows how the company funds its research and development and the commercialization of approved products.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Alkermes plc
Alkermes is a biopharmaceutical company specializing in diseases of the central nervous system. Unlike many biotech companies, it already has commercial products generating revenue. This chart shows how the company uses debt to fund the development of new drugs and market existing ones, balancing investment and profitability.
Market segment debt to market segment book capitalization - Pharma psycho
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart shows the overall debt burden in the psychopharmacology sector. It helps understand how the industry finances lengthy and risky clinical trials and how Alkermes manages its balance sheet.
Debt to book value of all companies in the market
Alkermes, a biopharmaceutical company, requires significant capital for R&D in the CNS field. This chart shows the overall debt level, reflecting investors' willingness to finance risk. For Alkermes, this is an important benchmark: how easy it is to raise funds for innovative but risky projects.
P/E of the company, segment and market as a whole
P/E - Alkermes plc
Alkermes plc is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart shows how the market assesses the profitability of its commercial products and the potential of new developments. This assessment is based on sales performance and clinical trial results.
P/E of the market segment - Pharma psycho
The pharmaceutical industry, particularly in the CNS area where Alkermes operates, requires significant investment in R&D. This chart shows the average valuation for biopharmaceutical companies. It helps understand how investors evaluate the balance between sales of Alkermes' existing drugs and the potential of its new developments.
P/E of the market as a whole
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and alcohol dependence. Its valuation depends on the commercial success of its products and the results of clinical trials. General market sentiment, reflected in this chart, has little impact on its value, which is determined by the specifics of the central nervous system market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Alkermes plc
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart reflects analyst expectations for the sales volumes of its key drugs and the success of new developments. It shows whether experts believe in the commercial potential of the company's portfolio.
%20P%2FE%20Alkermes%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alkermes-plc&v=1772597554391 "Chart of the company's future (projected) P/E Alkermes plc")
Future (projected) P/E of the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart compares Alkermes's future revenue expectations with those of the biotech sector. It demonstrates how the market views the commercial success of its existing drugs and the potential of its new developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772597554402 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Alkermes is a biopharmaceutical company specializing in medications for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart shows overall market sentiment. Alkermes' business is not dependent on economic cycles. The need for treatment for mental disorders is always present, ensuring stable demand for their products.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772597554409 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Alkermes plc
Alkermes is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart illustrates the company's financial journey, from research to sales. Profitability depends on the success of its commercialized drugs and progress in the development of new drugs.
Profit of companies in the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders, such as schizophrenia, bipolar disorder, and drug addiction. This chart shows the total profitability of the psychopharmacology sector, reflecting the progress in the development of new treatments and their market acceptance.
Overall market profit
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. Demand for their medications is driven by medical needs and is independent of economic conditions. This provides the company with a stable revenue stream, insulated from the cycles seen in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Alkermes plc
Alkermes is a biopharmaceutical company specializing in the treatment of central nervous system disorders, such as schizophrenia and addiction. Its future depends on sales of its existing drugs and the success of its new developments. This chart shows analyst expectations for the commercial potential of its drug portfolio.
%20profit%20of%20the%20company%20Alkermes%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alkermes-plc&v=1772597554491 "Graph of future (projected) profit of the company Alkermes plc")
Future (predicted) profit of companies in the market segment - Pharma psycho
Alkermes plc is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders, such as schizophrenia, bipolar disorder, and drug addiction. This chart shows forecasts for the biotech sector. Alkermes focuses on developing drugs with improved properties, such as longer-acting ones.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772597554505 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. Demand for its medications is driven by medical needs. This expected corporate profit curve affects it indirectly, through government healthcare budgets and the solvency of insurance companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772597554528 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Alkermes plc
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart shows how investors assess the commercial success of its existing products and the potential of new developments in its pipeline.
P/S market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. The company's revenue depends on sales of its commercial drugs. This chart shows the average valuation in the pharmaceutical industry, which helps understand how the market views Alkermes' product portfolio and commercial prospects.
P/S of the market as a whole
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. Its revenue is generated by sales of already approved drugs. This chart helps assess the market perception of the company's current revenue and its potential to develop new drugs in this complex area.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Alkermes plc
Alkermes plc is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and alcohol dependence. This chart reflects investor expectations for future sales of its commercial products and confidence in the potential of drugs in development.
%20P%2FS%20Alkermes%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alkermes-plc&v=1772597554754 "The graph of the company's future (projected) P/S Alkermes plc")
Future (projected) P/S of the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and bipolar disorder. This chart compares the company's future revenue expectations with its industry sector. It reflects the market's assessment of the commercial potential of its key drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772597554770 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. The optimism demonstrated by this indicator is often fueled by medical breakthroughs. Alkermes' success in developing new treatments for complex diseases influences the outlook for the entire sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772597554799 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Alkermes plc
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. Revenue, shown in this chart, comes from sales of its own drugs and royalties from partners for the use of its technologies in other medicines.
Sales of companies in the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. Their commercial success depends on sales of already approved drugs. This chart reflects the dynamics of the pharmaceutical market, where chronic disease treatments like Alkermes' generate a stable revenue stream.
Overall market sales
Alkermes plc, a biopharmaceutical company specializing in central nervous system disorders such as schizophrenia and addiction, has a lower demand for its medications than other companies. However, the overall revenue growth shown here improves the financial health of public and private payers, ensuring stable reimbursement for life-saving medications.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Alkermes plc
Alkermes is a biopharmaceutical company specializing in medications for the treatment of central nervous system disorders, such as schizophrenia, bipolar disorder, and addiction. Its sales forecast reflects market expectations for prescription volumes for its key medications and its ability to compete in complex therapeutic areas.
%20sales%20of%20the%20company%20Alkermes%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alkermes-plc&v=1772597554939 "Schedule of future (projected) sales of the company Alkermes plc")
Future (projected) sales of companies in the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders, such as schizophrenia, bipolar disorder, and addiction. This chart shows industry forecasts, helping to assess how Alkermes' drugs address complex and unmet medical needs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772597555041 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Alkermes, a biopharmaceutical company focused on central nervous system disorders such as schizophrenia and addiction, sees this chart as a marker of the stability of government healthcare funding. A stable economy, reflected here, ensures the predictability of Medicare/Medicaid payments, which is important for patient access to their treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772597555120 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Alkermes plc
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. Profitability depends on the success of its commercialized drugs and the ability to bring new ones to market. This chart shows how sales revenue covers significant research, development, and marketing expenses.
Market segment marginality - Pharma psycho
Alkermes is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart shows its financial performance in the context of the industry. The company's profitability depends on the commercial success of its key drugs and the ability to effectively manage research and marketing costs.
Market marginality as a whole
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This graph shows average profitability, but Alkermes operates in a complex and socially significant field. Their profitability depends on the success of their drugs and the needs of the healthcare system.
Employees in the company, segment and market as a whole
Number of employees in the company Alkermes plc
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. This chart shows the growth of its scientific and commercial teams. The increase in staff reflects both the development of new drugs and the marketing efforts of already approved medications.
Share of the company's employees Alkermes plc within the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. This chart shows the percentage of all scientists and clinicians in this complex therapeutic area that Alkermes attracts. This reflects its scientific contributions and commitment to helping patients with severe mental disorders.
Number of employees in the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. Its main assets are its team of scientists and commercial personnel. This chart shows how the company develops and markets its drugs. The growth in headcount reflects investments in R&D and efforts to commercialize its products.
Number of employees in the market as a whole
Alkermes is a biopharmaceutical company specializing in the treatment of central nervous system disorders, such as schizophrenia and addiction. Its growth is driven not by economics, but by the needs of the healthcare system and advances in drug development. This chart shows general trends, and Alkermes is an example of a sector where jobs are being created to solve complex medical problems.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Alkermes plc (ALKS)
Alkermes is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases. Its value is based on its portfolio of commercialized drugs and promising developments. The high value on this chart reflects the value of its team's intellectual property and successful R&D.
%20of%20the%20company%20Alkermes%20plc%20(ALKS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alkermes-plc-ALKS&v=1772597555455 "Chart of market capitalization per employee (in thousands of dollars) of the company Alkermes plc (ALKS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Alkermes is a biopharmaceutical company focused on CNS diseases (schizophrenia, addiction) and oncology. This chart shows the average capitalization per employee in the sector. It demonstrates how much the market values their R&D and pipeline of approved drugs per scientist.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772597555488 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Alkermes is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. Its value lies in its portfolio of commercialized products and development pipeline. This chart shows how the market values a successful biotech company, where revenue from patented drugs generates high revenue per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772597555529 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Alkermes plc (ALKS)
Alkermes is a biopharmaceutical company specializing in CNS disorders (schizophrenia, addiction). They have both their own drugs and receive royalties from others. This chart shows the effectiveness of their R&D and commercial teams. It reflects the company's ability to generate high profits per employee on patented drugs.
%20Chart%20Alkermes%20plc%20(ALKS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alkermes-plc-ALKS&v=1772597555585 "Company Profit Per Employee (in thousands of dollars) Chart Alkermes plc (ALKS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Alkermes (ALKS) is a biotech company focused on the "CNS" (schizophrenia, addiction). This chart shows the benchmark for "Pharma psycho" (Biotech). In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high. This is the "blockbuster business," where a single patent generates billions.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772597555596 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Alkermes (ALKS) is a biopharmaceutical company specializing in the development of drugs for the treatment of central nervous system disorders such as schizophrenia, bipolar disorder, and drug addiction. This chart, showing the average profit per employee across the market, serves as a backdrop. It helps to assess how biotechnology, where a single successful drug can recoup years of R&D, is a high-margin industry in terms of intellectual capital.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772597555728 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Alkermes plc (ALKS)
Alkermes is a biopharmaceutical company specializing in central nervous system disorders, such as schizophrenia and addiction. This chart shows the commercial success of their drugs. High revenue per employee indicates that their drugs are in demand and their team is working effectively on their production and marketing.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alkermes-plc-ALKS&v=1772597555819 "Sales chart per company employee Alkermes plc (ALKS)")
Sales per employee in the market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in central nervous system diseases (schizophrenia, addiction) and oncology. This chart shows the average revenue per employee in this segment. It allows us to assess how productive Alkermes' commercial team is in bringing its complex drugs to market compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Alkermes plc is a biopharmaceutical company specializing in central nervous system disorders (schizophrenia, addiction). They have commercialized drugs. This chart reflects how effectively their R&D and sales teams generate revenue from these complex drugs. It is an indicator of commercial success in a challenging therapeutic area.
Short shares by company, segment and market as a whole
Shares shorted by company Alkermes plc (ALKS)
Alkermes is a biopharmaceutical company specializing in central nervous system disorders (schizophrenia, addiction). Its business model includes both proprietary drugs and royalties. The chart reflects investor skepticism, perhaps concerned about patent expirations on key drugs or failures to develop new blockbusters capable of replacing older ones.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alkermes-plc-ALKS&v=1772597556109 "Short Shares Chart for the Company Alkermes plc (ALKS)")
Shares shorted by market segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in CNS disorders, such as schizophrenia and addiction. This chart reflects the overall pessimism in biotech. It demonstrates the general skepticism of investors: they may be concerned not only about problems with ALKS's drugs but also about regulatory barriers for the entire CNS drug industry.
Shares shorted by the overall market
Alkermes (ALKS) is a biopharmaceutical company (CNS, addiction). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with stable drug revenues, often suffer sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Alkermes plc (ALKS)
Alkermes is a biopharmaceutical company focused on the central nervous system (schizophrenia, addiction). Its business depends on the success of its key drugs. A chart above 70 may reflect strong sales or positive trial data. A level below 30 is often associated with concerns about competition or R&D failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alkermes-plc-ALKS&v=1772597556278 "RSI 14 indicator chart for the company's stock Alkermes plc (ALKS)")
RSI 14 Market Segment - Pharma psycho
Alkermes is a biopharmaceutical company specializing in central nervous system (CNS) disorders, such as schizophrenia, bipolar disorder, and alcohol dependence. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Alkermes compares to that.
RSI 14 for the overall market
Alkermes is a biopharmaceutical company specializing in the treatment of addictions and central nervous system disorders (schizophrenia). The company has commercial products, which provides stability. This market sentiment chart is important. During times of panic, investors may favor biotech companies with real sales, but they will still be wary of overall pressure on the sector.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALKS (Alkermes plc)
Alkermes (ALKS) is a biopharmaceutical company specializing in drugs for the treatment of central nervous system disorders, such as schizophrenia and addiction. This chart shows the average target price. It reflects analysts' forecasts for sales of existing drugs and the success of new developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALKS-Alkermes-plc&v=1772597556481 "A chart showing analyst consensus forecasts for the expected stock price. ALKS (Alkermes plc)")
The difference between the consensus estimate and the actual stock price ALKS (Alkermes plc)
Alkermes is an Irish biotech company specializing in drugs for the treatment of central nervous system disorders (schizophrenia, addiction). This chart measures the gap between the current share price and the consensus target price. It shows how confident experts are in the commercial success of their key drugs and new developments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALKS-Alkermes-plc&v=1772597556491 "A chart showing the difference between the consensus forecast and the actual stock price. ALKS (Alkermes plc)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Alkermes is a biopharmaceutical company focused on complex CNS disorders (schizophrenia, addiction). It has both commercial drugs and an R&D pipeline. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe the mental health treatment market will grow.
Analysts' consensus forecast for the overall market share price
Alkermes (ALKS) is a biotech company specializing in CNS drugs (for schizophrenia and addiction). This overall market sentiment chart is important for biotech. Market optimism = easy access to capital to fund expensive R&D. In a crisis (pessimism), investors may value Alkermes for its existing, revenue-generating drugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Alkermes plc
Alkermes is a biotech company specializing in the treatment of central nervous system (CNS) disorders, such as schizophrenia, addiction, and depression. This chart evaluates their CNS drug portfolio. It weighs stable royalties from licensed products against the commercial success of their own, recently launched drugs.
AKIMA Market Segment Index - Pharma psycho
Alkermes is a biotech focused on the CNS (Central Nervous System); the company develops and markets complex drugs for the treatment of schizophrenia, depression, and addiction. This summary metric evaluates R&D. The graph shows the segment average. This benchmark provides insight into how Alkermes's complex (CNS) niche differentiates it from the average pharmaceutical company.
The AKIM Index for the overall market
Alkermes is a biotech company focused on the central nervous system (CNS). It develops treatments for schizophrenia, depression, and addiction. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this protective scientific story, rooted in biotech, compares to overall economic trends.
